Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Neuromodulation of Sleep and Mood: A Multimodal Biomarker Study of Non-Invasive Vagal Nerve Stimulation (MOSAIC-VNS)

ClinicalTrials.gov ID: NCT07945015

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07945015. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 10:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to learn how non-invasive cervical transcutaneous vagus nerve stimulation (ctVNS) - a treatment given by holding a small hand-held device against the right part of your neck (cervical vagus nerve) - affects sleep, heart rhythm, mood, and certain markers in the blood and some genetic material. The main questions it aims to answer are: 1. Will ctVNS enhance both subjective and objective sleep continuity and regularity, improve circadian stability, and increase parasympathetic HRV indices compared with the end-of-sham baseline? 2. Will improvements in HRV and sleep be associated with greater improvement in standardized depression ratings, with treatment effects mediated in part by improvements in sleep and in part by sleep-independent autonomic mechanisms? 3. Will ctVNS modify the expression of miRNAs related to sleep, stress, inflammation, and neuroplasticity, and baseline or early-change miRNA profiles, combined with physiological data, and may help distinguish responders from non-responders? This study lasts about 7 weeks. Participants will be asked to do the following: Visit 1/ Baseline (in person): * Participants will answer questions about their health, mood, and sleep; * have their blood pressure and pulse taken; * give about 28 mL (about 6 teaspoons) of blood - 20 mL for the research measurements and 8 mL for routine safety blood tests; * be fitted with a wrist device that measures your heart rate, physical activity and sleep; and be given the study device with training on how to use it at home. This visit will last about 2 hours. Weeks 1-6 (at home): * Participants will use the study device (nerve stimulator) twice a day (morning within 1 hour of waking, and evening within 1 hour of your usual bedtime), each use lasting about 2 minutes; * Participants will also need to wear the wrist device day and night; * Participants will fill out a short sleep diary each morning. Visit 2/ Week 2 (in person) and Visit 3/ Week 6 (in person): * Participants will repeat the questionnaires and interviews from Visit 1; * have their blood pressure and pulse taken; * give another blood sample of about 20 mL; * have the data from their wrist device downloaded. * At each in-person visit after visit 1, their study device will be checked and may be exchanged for another device. This visit will last about 1.5 - 2 hours. The investigators will call participants on the phone to check-in at Weeks 1, 3, and 5, and a safety call at Week 7. These phone calls will last about 15 minutes.

Study identification

NCT ID
NCT07945015
Recruitment status
Not yet recruiting
Study type
Interventional
Phase
Not applicable
Enrollment
40 participants

Conditions and interventions

Interventions

Device

Eligibility (public fields only)

Age range
18 Years to 50 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 1, 2026 (Estimated)
Primary completion
Sep 30, 2028 (Estimated)
Completion
Jan 1, 2029 (Estimated)
Last update posted
Nov 18, 2026

2026 – 2029

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
University of Alabama at Birmingham (UAB) Birmingham Alabama 35294 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07945015, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 18, 2026 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.